Farreny A, Aguado J, Corbera S, Ochoa S, Huerta-Ramos E, Usall J. Baseline predictors for success following strategy-based cognitive remediation group training in schizophrenia. J Nerv Ment Dis. 2016 Aug;204(8):585-9. doi: 10.1097/NMD.0000000000000509
Earnshaw SR, Kauf TL, McDade C, Potashman MH, Pauyo C, Reese ES, Senagore A. Economic impact of alvimopan considering varying definitions of postoperative ileus. J Am Coll Surg. 2015 Nov;221(5):941-50. doi: 10.1016/j.jamcollsurg.2015.08.004
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs. 2013 Dec;31(6):1573-9.
Inabnet WB3rd, Winegar DA, Sherif BN, Sarr MG. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg. 2012 Apr;214(4):550-6.
Godding PR, McAnulty RD, Wittrock DA, Britt DM, Khansur T. Predictors of depression among male cancer patients. J Nerv Ment Dis. 1995 Feb 1;183(2):95-8.